Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas
Nov 05, 2026
Read MoreZai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
Nov 05, 2026
Read MoreZai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Oct 23, 2026
Read MoreZai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
Oct 21, 2026
Read MoreZai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
Oct 14, 2026
Read MoreZai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sep 29, 2026
Read MoreZai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Aug 17, 2026
Read More